Dr. Wolchok Describes the Immunotherapy Ipilimumab

Video

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab

Jedd D. Wolchok, MD, PhD from Memorial Sloan-Kettering Cancer Center describes the immunotherapy ipilimumab.

Dr. Wolchok says ipilimumab has moved cancer immunotherapy ahead to an important next step. He says high dose Interleukin 2 was the first clear cut example of how pure immune immodulation could lead to control of cancer. The difficulties with IL-2 in terms of side effects and the fact that patients using it sometimes had to be admitted to the hospital limited its use. Although IL-2 is not being compared head to head with ipilimumab, Dr. Wolchok says the kinds of durable responses seen with ipilimumab are reminiscent of immunotherapy. It is an easier drug to give with side effects that, in general, are manageable.

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center